Psychiatr Prax 2014; 41(03): 148-152
DOI: 10.1055/s-0033-1343204
Originalarbeit
© Georg Thieme Verlag KG Stuttgart · New York

Effektivität der Dialektisch-Behavioralen Therapie (DBT) in der tagesklinischen Behandlung der Borderline-Persönlichkeitsstörung – Bedeutung von Medikation und Behandlungskosten

Effectiveness of Dialectical Behavior Therapy (DBT) in an Outpatient Clinic for Borderline Personality Disorders – Impact of Medication Use and Treatment Costs
Christoph Richter
1   Vivantes Wenckebach-Klinikum, Psychiatrie, Psychotherapie und Psychosomatik/ Gerontopsychiatrie
2   Charité – Universitätsmedizin Berlin, Klinik für Psychiatrie und Psychotherapie, Charité Campus Mitte
,
Brigitte Heinemann
1   Vivantes Wenckebach-Klinikum, Psychiatrie, Psychotherapie und Psychosomatik/ Gerontopsychiatrie
,
Mathias Kehn
1   Vivantes Wenckebach-Klinikum, Psychiatrie, Psychotherapie und Psychosomatik/ Gerontopsychiatrie
,
Bruno Steinacher
1   Vivantes Wenckebach-Klinikum, Psychiatrie, Psychotherapie und Psychosomatik/ Gerontopsychiatrie
› Author Affiliations
Further Information

Publication History

Publication Date:
03 June 2013 (online)

Preview

Zusammenfassung

Anliegen: Nachweis der Effektivität tagesklinischer Therapie bei Borderline-Persönlichkeitsstörungen (BPS).

Methode: Naturalistische, offene Beobachtungsstudie einer 12-wöchigen zertifizierten tagesklinischen DBT. Erhebung von Symptom-Checkliste (SCL-90), Beck-Depressions-Inventar (BDI) und Borderline-Symptomliste 95 (BSL-95) in der 1. und 11. Woche sowie Dokumentation der Pharmakotherapie.

Ergebnisse: Einschluss von 31 Fällen. Verbesserung im BDI um 50,8 % (p < 0,001), in der SCL-90 um 42,9 % (p < 0,01) und der BSL-95 um 48,4 % (p < 0,001) (Power = 0,99). Es fand sich kein Zusammenhang zwischen Medikationsänderung und Symptomreduzierung.

Schlussfolgerungen: Erstmals wurde die Effektivität einer teilstationären DBT belegt.

Abstract

Objective: Investigation of the clinical effectiveness of dialectical behavioral therapy in a day clinic setting (DBT-DC) for borderline personality disorders (BPD), and impact of medication and daily costs.

Methods: In a prospective, naturalistic, open and uncontrolled design BPD patients were enclosed in a 12-week DBT-DC. This DBT-program was certified by the German network of DBT. We collected data from the Symptom Checklist (SCL-90), the Beck Depression Inventory (BDI) and the Borderline Symptom List 95 (BSL-95) in the first and at the end of the 11th week. The concomitant medication and its changes were described.

Results: 31 cases were included (9 drop-outs: 29 %). The average age was 33.3 years (18 – 52, SD = 10.6). 21 females and one male completed the program. There was no relationship between changes of BDI, SCL-90 and BSL-95 scores (p < 0.001) and medication (and its alteration). The BDI scores improved by 50.8 % (p < 0.001), the SCL-90 by 42.9 % (p < 0.01) and the BSL-95 by 48.4 % (p < 0.001). The power was 0.99 (α = 0.05), the effect size was 1.41. In our setting the daily costs showed a reduction of about 6500 € per case compared to an inpatient DBT. Medications played no significant role for improvement.

Conclusions: For the first time a partial remission for BPD patients after 12 weeks has been shown to be achieved in a DBT-DC setting. DBT-DC reduces the primary costs of BPD compared to a specific inpatient therapy.